FDA backs Pfizer COVID-19 boosters for seniors, high-risk
The U.S. moved a step closer Wednesday to offering booster doses of Pfizer’s COVID-19 vaccine to senior citizens and others at high risk from the virus as the Food and...
All Stories
FDA panel is first key test for Biden’s COVID-19 booster plan
The Biden administration’s embattled plan to dispense COVID-19 booster shots to most Americans faced its first major hurdle Friday as a government advisory panel met to decide whether to endorse...
What does full approval of Pfizerās COVID-19 vaccine mean?
Public health experts hope the change will convince more unvaccinated people to get the shot and spur more employers to require vaccinations.
FDA gives full approval to Pfizer COVID-19 vaccine
The U.S. gave full approval to Pfizer's COVID-19 vaccine on Monday, a milestone that may help lift public confidence in the shots as the nation battles the most contagious coronavirus...
U.S. health officials call for booster shots against COVID-19
U.S. health officials Wednesday announced plans to offer COVID-19 booster shots to all Americans to shore up their protection amid the surging delta variant and evidence that the vaccines' effectiveness...
More protection: U.S. likely to authorize COVID-19 booster shots
After struggling for months to persuade Americans to get the COVID-19 vaccine, U.S. health officials could soon face a fresh challenge: talking vaccinated people into getting booster shots to gain...
Extra COVID vaccine OK’d for those with weak immune systems
U.S. regulators on Thursday said transplant recipients and others with severely weakened immune systems can get an extra dose of the Pfizer or Moderna COVID-19 vaccines to better protect them...
FDA adds warning of rare reaction risk to Johnson & Johnson COVID vaccine
U.S. regulators on Monday added a new warning to Johnson & Johnson’s COVID-19 vaccine about links to a rare and potentially dangerous neurological reaction, but said it’s not entirely clear...
Does new Alzheimerās drug work? Answers may miss 2030 target.
When a controversial Alzheimerās drug won U.S. approval, surprise over the decision quickly turned to shock at how long it might take to find out if it really works ā...
U.S. to spend $3.2B for antiviral pills for COVID-19, Dr. Anthony Fauci says
The United States is devoting $3.2 billion to advance development of antiviral pills for COVID-19 and other dangerous viruses that could turn into pandemics.